WO2002026325A3 - Restoration of perturbed barrier function by application of antiandrogens - Google Patents

Restoration of perturbed barrier function by application of antiandrogens Download PDF

Info

Publication number
WO2002026325A3
WO2002026325A3 PCT/US2001/042403 US0142403W WO0226325A3 WO 2002026325 A3 WO2002026325 A3 WO 2002026325A3 US 0142403 W US0142403 W US 0142403W WO 0226325 A3 WO0226325 A3 WO 0226325A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiandrogens
restoration
application
barrier function
perturbed
Prior art date
Application number
PCT/US2001/042403
Other languages
French (fr)
Other versions
WO2002026325A9 (en
WO2002026325A2 (en
Inventor
Peter M Elias
Kenneth R Feingold
Original Assignee
Univ California
Us Gov Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Us Gov Veterans Affairs filed Critical Univ California
Priority to AU2002213433A priority Critical patent/AU2002213433A1/en
Publication of WO2002026325A2 publication Critical patent/WO2002026325A2/en
Publication of WO2002026325A3 publication Critical patent/WO2002026325A3/en
Publication of WO2002026325A9 publication Critical patent/WO2002026325A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Abstract

Disorders of the skin and mucous membranes that have a disrupted or dysfunctional epidermal barrier are treated or prevented by the administration of antiandrogens, including antagonists of the androgen receptor, inhibitors of the conversion of testosterone to dihydrotestosterone, and agents that suppress androgen production at the level of the hypothalamic-pituitary axis.
PCT/US2001/042403 2000-09-29 2001-09-27 Restoration of perturbed barrier function by application of antiandrogens WO2002026325A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213433A AU2002213433A1 (en) 2000-09-29 2001-09-27 Restoration of perturbed barrier function by application of antiandrogens

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67615500A 2000-09-29 2000-09-29
CA002321406A CA2321406A1 (en) 2000-09-29 2000-09-29 Restoration of perturbed barrier function by application of antiandrogens
US09/676,155 2000-09-29

Publications (3)

Publication Number Publication Date
WO2002026325A2 WO2002026325A2 (en) 2002-04-04
WO2002026325A3 true WO2002026325A3 (en) 2002-08-22
WO2002026325A9 WO2002026325A9 (en) 2003-02-13

Family

ID=25682128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042403 WO2002026325A2 (en) 2000-09-29 2001-09-27 Restoration of perturbed barrier function by application of antiandrogens

Country Status (3)

Country Link
AU (1) AU2002213433A1 (en)
CA (1) CA2321406A1 (en)
WO (1) WO2002026325A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
WO1999062464A1 (en) * 1998-06-04 1999-12-09 Ben Gurion University Of The Negev Research And Development Authority Topical composition for treatment of baldness

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
WO1999062464A1 (en) * 1998-06-04 1999-12-09 Ben Gurion University Of The Negev Research And Development Authority Topical composition for treatment of baldness

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GWIEZDZINSKI, Z. ET AL.: "2,5% solution of flutamide (a nonsteriodal antiandrogen) in the topical treatment of acne vulgaris. A double-blind randomized study", JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 8, no. 2, June 1997 (1997-06-01), pages 75 - 78, XP008002847 *

Also Published As

Publication number Publication date
WO2002026325A9 (en) 2003-02-13
CA2321406A1 (en) 2002-03-29
AU2002213433A1 (en) 2002-04-08
WO2002026325A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
WO2004018386A3 (en) Acetophenone potentiators of metabotropic glutamate receptors
WO2011014588A3 (en) Dermal formulations of dp2 receptor antagonists
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
WO2006009734A8 (en) Gonadotropin releasing hormone receptor antagonists
WO2002017930A3 (en) Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
DE60113290D1 (en) TREATMENT OF SEXUAL FUNCTIONAL TROUBLESHOOTING WITH BOMBESIN RECEPTOR ANTAGONISTS
DK1135153T3 (en) Uses of EPH receptor antagonists and agonists for the treatment of vascular disorders
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
WO2002017895A3 (en) Use of an aldosterone receptor antagonist to improve cognitive function
WO2006066011A3 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
WO2001074773A3 (en) Phenyl-substituted indoles as histamine h3-receptor antagonists
WO2004009616A3 (en) Ghrelin analogs
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
CA2409771A1 (en) Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
AU2001280804A1 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
WO2002072093A3 (en) Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
WO2004022725A3 (en) Chia seeds
WO2001046455A3 (en) Survivin promotion of angiogenesis
WO2002026325A3 (en) Restoration of perturbed barrier function by application of antiandrogens
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
PL369978A1 (en) Compositions based on aqueous dispersions of bitumen and polyurethane, method for the preparation thereof, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP